Abstract: . . .  87 Chapter 11. Hypertensive Vascular Disease Pierre Larochelle, M.D., Ph.D. 1 Maxime Lamarre-Cliche, M.D. 2 1 Directeur de la recherche clinique Unit de recherche en pharmacologie cardiovasculaire Institut de recherche clinique . . .
. . .  removal of the monitor, take a final manual reading using the start/stop button. The final manual reading should occur as close to 24 hours since prior dosing as recorded on the CRF. (The patient might need to repeat the ABPM if the monitoring is < 24 hours in duration, reference Appendix 11.3.3.) If you see Ecxx (i.e. error code) on the ABPM display, take another reading to ensure you have a captured BP reading. Remove the monitor from the patients arm. 8. After downloading of your patients data is complete, you may initialize the monitor for future use, making . . .
. . .  (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. 8. Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-56. 9. Blood Pressure Lowering Treatment TrialistsCollaboration. Effects of different blood-pressure- lowering regimens . . .
. . .  in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-56. 9. Blood Pressure Lowering Treatment TrialistsCollaboration. Effects of different blood-pressure- lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35. Page 15 101 APPENDIX 1 Canadian Hypertension Recommendations Recommended techniques for measuring blood pressure 1. Measurements . . .
. . .  standard of care and geographic region in which the participant's clinical site was located. Analyses of primary and secondary events considered censoring due to losses to follow-up (e.g., participants for whom the primary event status was unknown on the closing date), non-cardiovascular disease -related deaths (as appropriate), and the closing date of the study. Losses were censored at the date the primary event status was last known (either the date provided by the site during the closeout process; or the date of the last follow-up visit). The proportional hazards assumption . . .
--3000,5,300,3115,62788